Kamble R, Raju G M, Kumar L, Kochupillai V
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi.
Indian J Med Res. 1997 Jan;105:1-8.
Mobilized peripheral blood haematopoietic progenitor cells are increasingly being used as against bone marrow (BM) transplants, following high dose chemotherapy and/or radiotherapy for the management of chemosensitive malignancies. Rapid haematopoietic reconstitution as evidenced by reduced duration of neutropaenia, fewer donor platelet infusions, shorter hospital stay and reduced cost of treatment are the advantages of this procedure. Reduced tumour cell contamination of mobilized blood compared to bone marrow however, has not been substantiated. Mobilization of lymphokine activated killer cells (LAK), use of blood stem cells (BSC) for allogeneic transplants and ex vivo expansion of the mobilized cells are emerging as the future areas for research. Addition of interleukin-3 (IL-3), stem cell factor (c-kit ligand) and PIXY-321 appear to open-up new vistas by enforcing trilineage and multilineage haematopoietic reconstitution.
在对化疗敏感的恶性肿瘤进行大剂量化疗和/或放疗后，动员的外周血造血祖细胞越来越多地被用于替代骨髓移植。中性粒细胞减少持续时间缩短、供体血小板输注次数减少、住院时间缩短以及治疗成本降低所证明的快速造血重建是该方法的优点。然而，与骨髓相比，动员血液中肿瘤细胞污染减少这一点尚未得到证实。淋巴因子激活的杀伤细胞（LAK）的动员、用于同种异体移植的血液干细胞（BSC）的使用以及动员细胞的体外扩增正在成为未来的研究领域。添加白细胞介素-3（IL-3）、干细胞因子（c-kit配体）和PIXY-321似乎通过促进三系和多系造血重建开辟了新的前景。
